Apellis Pharmaceuticals' Syfovre, a treatment for geographic atrophy, has received FDA approval.
It is the first and only treatment that has been approved for geographic atrophy, a leading cause of blindness, according to a Feb. 17 news release.
Syfovre is set to be available to specialty distributors and pharmacies across the country in March.